Energenesis Biomedical Co (TPE:6657) Additional Paid-In Capital : NT$518.15 Mil(As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Energenesis Biomedical Co Additional Paid-In Capital?

Energenesis Biomedical Co's quarterly additional paid-in capital increased from Sep. 2024 (NT$59.22 Mil) to Dec. 2024 (NT$64.62 Mil) and increased from Dec. 2024 (NT$64.62 Mil) to Mar. 2025 (NT$518.15 Mil).

Energenesis Biomedical Co's annual additional paid-in capital increased from Dec. 2022 (NT$199.77 Mil) to Dec. 2023 (NT$393.90 Mil) but then declined from Dec. 2023 (NT$393.90 Mil) to Dec. 2024 (NT$64.62 Mil).

Energenesis Biomedical Co Additional Paid-In Capital Historical Data

The historical data trend for Energenesis Biomedical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Energenesis Biomedical Co Additional Paid-In Capital Chart

Energenesis Biomedical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

206.93

307.62

199.77

393.90

64.62

Energenesis Biomedical Co Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															396.52	55.48	59.22	64.62	518.15

Energenesis Biomedical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Energenesis Biomedical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Energenesis Biomedical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Energenesis Biomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Energenesis Biomedical Co Ltd (TPE:6657) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492

Website

https://www.energenesis-biomedical.com

Energenesis Biomedical Co Ltd is a biomedicine company. It is engaged in businesses related to biological experimentation and analysis, as well as new drug development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. Its product pipeline consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream, among others.

Energenesis Biomedical Co Headlines

No Headlines